The data emerging here reported are in line with the current literature and validate the pivotal role of PNPLA3 variants in MASLD, highlighting the multisystemic implications of the metabolic disruption caused by the abnormal PNPLA3 function in hepatocytes [5,16,17,18,19]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.